Mitigating Heat and Air Pollution Exposure in Older Adults with Hypertension

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The trial investigates a combined behavioral and technical intervention aimed at reducing personal exposure to heat and indoor air pollutants in adults aged 65 and older with hypertension. It uses wearable and indoor sensors to measure changes in ambient temperature exposure, as well as indoor air quality and circadian blood pressure patterns via actigraphy. Participants will follow heat-mitigation behaviors and use air-cleaning or filtration measures in their homes, with exposure and health outcomes assessed over time. The study is conducted in aging populations in Barcelona and Nicosia, with outcomes focusing on exposure reduction and blood pressure circadian variation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged ≥65 years
* Living in Barcelona (Spain) or Nicosia (Cyprus) metropolitan areas
* Have a physician's diagnosis of arterial hypertension
* Receive daily anti-hypertensive medication
* Clinically stable

Exclusion Criteria:

* Currently smoking
* Presence of any smoking residents in the household
* Not residing at the household for at least 5 days a week
* Planning to move from the current home within the next two months
* No access to Wi-Fi or 4G/5G mobile phone
* Severe chronic conditions (congestive heart failure, ischemic heart disease, significant valvular heart disease, diabetes mellitus type 2 (DM2), inflammatory diseases, renal failure, or active cancer)
* Illicit drugs abuse
* Alcohol abuse
* Psychiatric disorders
* Severe mental disability that interferes with answering questions or following instructions

Where it's running

• Medical School, University of Cyprus
  Nicosia, Cyprus Recruiting
• Vall d'Hebron Institut de Recerca (VHIR)
  Barcelona, Spain Recruiting

Study contacts

• Principal investigator: Panayiotis Yiallouros, Professor — University of Cyprus
• Study coordinator: Panayiotis Yiallouros, Professor
• Email: yiallouros.panayiotis@ucy.ac.cy
• Phone: +35722895212

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using echocardiograms and patient data to diagnose cardiac diseases

  This study is testing if using advanced technology to analyze heart ultrasound images along with patient information can help doctors better diagnose heart diseases.

  Recruiting Hospices Civils de Lyon · Pierre-Bénite · NCT05942729

• Understanding how low-load leg exercises affect muscle and blood flow in PAH patients

  This substudy tests whether a gentle leg exercise program can change blood flow and oxygen use in the calf muscles of adults with pulmonary arterial hypertension.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT07781709

• Sotatercept in Japanese children with pulmonary arterial hypertension

  This study tests whether sotatercept is safe and well tolerated in Japanese children with PAH when added to standard PAH treatment.

  Recruiting at 3 sites Phase 2 Merck Sharp & Dohme LLC · Izumi, Osaka and 2 other locations · NCT07646860

• DIAG723 in Adults With HHT

  A first-in-human study tests DIAG723 versus placebo in adults with hereditary hemorrhagic telangiectasia to see if it is safe and possibly helpful.

  Recruiting at 3 sites Phase 1/2 Diagonal Therapeutics, Inc. · Camperdown, New South Wales and 10 other locations · NCT07623525

• See if 18F-FAPI-74 PET/CT can better detect fibrosis in heart and lung disease

  Researchers are testing a new PET/CT tracer, 18F-FAPI-74, to see if it can reveal early fibrotic changes in people with heart and lung diseases who are at risk for tissue scarring.

  Recruiting Phase 3 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07613099

• Sotatercept in Indian adults with pulmonary arterial hypertension on standard therapy

  This study tests whether adding sotatercept to current PAH medicines is safe and tolerable for adults with PAH in India.

  Recruiting at 3 sites Phase 4 Merck Sharp & Dohme LLC · Hyderabad, Andhra Pradesh and 2 other locations · NCT07600723

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.